

# A Study on Global Clinical Approval of Exosome-Based Therapeutics Loaded with Anti-inflammatory Proteins for Treatment of ‘Disease A’

ILIAS Biologics Inc.



| OTHERS                   | Preclinical   |
|--------------------------|---|
| Product Type             | Other-Bio.  |
| Indication               | ‘Disease A’   |
| Target                   | Intracellular regulatory pathway controlling disease-associated signaling   |
| MoA(Mechanism of Action) | Exo-‘B’ enables targeted intracellular delivery of therapeutic proteins designed to modulate specific signaling pathways involved in disease progression  |
| Competitiveness          | <ul style="list-style-type: none"> <li>- Provides a novel and durable therapeutic approach by addressing the underlying cause of disease progression rather than temporary symptom control</li> <li>- Designed to achieve cell-selective modulation through targeted intracellular delivery, offering potential for improved efficacy and safety</li> <li>- Enables chronic and maintenance treatment with minimal systemic burden, representing a non-invasive and sustainable alternative to existing standard therapies</li> </ul> |
| Development Stage        | Preclinical   |
| Route of Administration  | Injection   |

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*